Abacavir substitution for nucleoside analogs in patients with HIV lipoatrophy: A randomized trial

Journal of the American Medical Association

Volumn 288, Issue 2, 2002, Pages 207-215

  Carr, Andrew ^a   Workman, Cassy ^b   Smith, Don E ^c   Hoy, Jennifer ^e   Hudson, Jeff ^b,d   Doong, Nicholas ^d   Martin, Allison ^c   Amin, Janaki ^c   Freund, Judith ^a   Law, Matthew ^c   Cooper, David A ^a,c  

^a St Vincents Hospital   (United States)

^b AIDS Research Initiative   (United States)

^c UNIVERSITY OF NEW SOUTH WALES   (Australia)

^d Burwood Road Medical Centre ^*  (Australia)

^e MONASH UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ADEFOVIR; ANTIRETROVIRUS AGENT; CD4 ANTIGEN; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; INDINAVIR; LAMIVUDINE; LOPINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; VIRUS RNA; ZIDOVUDINE;

ADIPOCYTE; ADULT; ARTICLE; BODY COMPOSITION; CLINICAL TRIAL; DRUG HYPERSENSITIVITY; DRUG INDUCED DISEASE; DRUG SAFETY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LEUKOCYTE COUNT; LIPID BLOOD LEVEL; LIPODYSTROPHY; MAJOR CLINICAL STUDY; MALE; METABOLIC PARAMETERS; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; QUALITY OF LIFE; TREATMENT FAILURE; TREATMENT OUTCOME; VIRUS INFECTION; VIRUS LOAD;

EID: 0037055028     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.288.2.207     Document Type: Article

References (32)

1. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors
2. Visceral abdominal-fat accumulation associated with use of indinavir
3. "Buffalo hump" in men with HIV-1 infection
4. Diagnosis, prediction and natural course of HIV protease inhibitor-associated lipodystrophy, hyperlipidaemia and diabetes mellitus
5. Clinical assessment of HIV-associated lipodystrophy in an ambulatory population
6. Lipodystrophy, metabolic disorders, and human immunodeficiency virus infection
7. Risk of lipodystrophy in HIV-1-infected patients treated with protease inhibitors
8. Failure to maintain long-term adherence to highly active antiretroviral therapy
9. Inhibition of adipocyte differentiation by HIV protease inhibitors
10. Stimulation of vitamin A, acid signaling by the HIV protease inhibitor indinavir
11. The HIV protease inhibitor indinavir impairs sterol regulatory element-binding protein-1 intranuclear localization, inhibits preadipocyte differentiation, and induces insulin resistance
12. Redistribution of body fat in HIV-infected women undergoing combined antiretroviral therapy
13. Lipodystrophy in patients naive to HIV protease inhibitors
14. A syndrome of peripheral fat wasting dipodystrophy) in patients receiving long-term nucleoside analogue therapy
15. A syndrome of lipoatrophy, lactic acidaemia and liver dysfunction associated with HIV nucleoside analogue therapy
16. Contribution of nucleoside analogue reverse transcriptase inhibitors to subcutaneous fat wasting in patients with HIV infection
17. Effects of nucleoside reverse transcriptase inhibitors on adipogenesis and adipocyte metabolism
18. Raised lactate levels are common and may be predictive of subcutaneous fat wasting
19. Mitochondrial DNA decrease in subcutaneous adipose tissue of HIV-infected individuals with peripheral lipoatrophy
20. HIV protease inhibitor substitution in patients with lipodystrophy
21. The effects of discontinuing stavudine therapy on clinical and metabolic abnormalities in patients suffering from lipodystrophy
22. A randomised trial of thymidine analogue withdrawal in lipoatrophic HIV patients virologically controlled on protease inhibitor sparing therapy
23. Toxicity of antiviral nucleoside analogs and the human mitochondrial DNA polymerase
24. Capturing the paradigm shift in HIV treatment
25. A randomised, open-label comparison of three highly active antiretroviral therapy regimens including two nucleoside analogues and indinavir for previously untreated HIV-1 infection
26. Hypersensitivity reactions during therapy with the nucleoside reverse transcriptase inhibitor abacavir
27. Variations in population health status
28. Analysis of HIV-1 clinical trials
29. Adverse effects of antiretroviral therapy
30. Studies of body composition and fat distribution in HIV-infected and control subjects
31. Efficacy and safety of troglitazone in the treatment of lipodystrophy syndromes